AbbVie slammed over ‘drip feed’ of Imbruvica patents
20-07-2020
Ascannio / Shutterstock.com
The US Patent Trial and Appeal Board (PTAB) has invalidated parts of an AbbVie patent covering blood disease drug Imbruvica (ibrutinib).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Imbruvica, AbbVie, Sandoz, Novartis, PTAB, ibrutinib, GVHD, I-MAK